PL1622629T3 - Kompozycja do kontrolowanego uwalniania zawierająca sól strontu - Google Patents

Kompozycja do kontrolowanego uwalniania zawierająca sól strontu

Info

Publication number: PL1622629T3
Authority: PL; Poland
Prior art keywords: controlled; composition containing; release composition; strontium salt; strontium
Prior art date: 2003-05-07

Application number

PL04731307T

Other languages

English (en)

Inventor

Christian Hansen

Henrik Nilsson

Jens E T Andersen

Stephan Christgau

Original Assignee

Osteologix As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-07

Filing date

2004-05-06

Publication date

2013-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33437112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1622629(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-05-06 Application filed by Osteologix As filed Critical Osteologix As

2013-12-31 Publication of PL1622629T3 publication Critical patent/PL1622629T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Diabetes (AREA)
Neurology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL04731307T 2003-05-07 2004-05-06 Kompozycja do kontrolowanego uwalniania zawierająca sól strontu PL1622629T3 (pl)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
DKPA200300691		2003-05-07
DKPA200301043		2003-07-08
US52840903P	2003-12-09	2003-12-09
DKPA200301821		2003-12-09
EP04731307.7A EP1622629B1 (en)	2003-05-07	2004-05-06	Controlled-release composition containing a strontium salt
PCT/DK2004/000326 WO2004098617A2 (en)	2003-05-07	2004-05-06	Controlled release composition containing a strontium salt

Publications (1)

Publication Number	Publication Date
PL1622629T3 true PL1622629T3 (pl)	2013-12-31

Family

ID=33437112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04731307T PL1622629T3 (pl)	2003-05-07	2004-05-06	Kompozycja do kontrolowanego uwalniania zawierająca sól strontu

Country Status (7)

Country	Link
US (3)	US20060216358A1 (pl)
EP (1)	EP1622629B1 (pl)
JP (2)	JP5049589B2 (pl)
AU (2)	AU2004237437B2 (pl)
CA (1)	CA2524603C (pl)
PL (1)	PL1622629T3 (pl)
WO (1)	WO2004098617A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2524610C (en) *	2003-05-07	2014-03-25	Osteologix A/S	Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
PL1534305T3 (pl)	2003-05-07	2007-03-30	Osteologix As	Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
US20080167513A1 (en) *	2004-02-26	2008-07-10	Osteologlx A/S	Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions
CN101010087B (zh)	2004-05-06	2012-06-27	奥斯泰奥洛吉斯公司	用于制备金属有机盐的高收率和快速的合成方法
US20090035315A1 (en) *	2004-06-17	2009-02-05	Stephan Christgau	Method of Improving Treatments in Rheumatic and Arthritic Diseases
DE602005016803D1 (de) *	2004-06-25	2009-11-05	Strontin Aps	Zusammensetzungen mit strontium und vitamin d und ihre verwendungen
HUE028342T2 (en)	2004-10-08	2016-12-28	Forward Pharma As	Pharmaceutical preparations containing controlled release fumaric acid ester
WO2007003200A2 (en) *	2005-07-06	2007-01-11	Osteologix A/S	High yield synthesis methods for producing organic salts of strontium
EP3332788B1 (en)	2006-02-03	2025-10-15	Opko Renal, LLC	Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
US20070218111A1 (en) *	2006-03-16	2007-09-20	Western Holdings, Llc	Strontium compositions for bones
EP2037936B1 (en)	2006-06-21	2014-06-11	Proventiv Therapeutics, LLC	Method of treating and preventing secondary hyperparathyroidism
JP2008063279A (ja) *	2006-09-07	2008-03-21	Univ Of Ryukyus	血糖上昇予防・治療剤
PL2097137T3 (pl) *	2006-11-21	2013-02-28	Mokwalo Spf S A	Kompozycje zawierające stront i ich zastosowanie w leczeniu lub zapobieganiu zapaleniu dziąseł, zapaleniu przyzębia, zapaleniu przyzębia będącemu manifestacją chorób układowych i martwiczym chorobom przyzębia
CA2943032C (en)	2007-04-25	2019-05-07	Cytochroma Inc.	Oral controlled release compositions comprising vitamin d compound and waxy carrier
EP2022447A1 (en)	2007-07-09	2009-02-11	Astra Tech AB	Nanosurface
PT2564839T (pt)	2009-01-09	2016-07-14	Forward Pharma As	Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão
EP2416756A2 (en)	2009-04-10	2012-02-15	Mahmut Bilgic	Stable pharmaceutical compositions with high bioavailibility
EP2266638A3 (de) *	2009-06-25	2014-08-13	Biotronik VI Patent AG	Biokorrodierbares Implantat mit einer aktiven Beschichtung
FR2953139B1 (fr) *	2009-11-27	2012-04-13	Servier Lab	Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
EP2552484B1 (en)	2010-03-29	2020-01-08	Opko Ireland Global Holdings, Ltd.	Methods and compositions for reducing parathyroid levels
EP2530068A1 (en)	2011-05-31	2012-12-05	Lacer, S.A.	New strontium salts, synthesis and use thereof in the treatment of osteoporosis
WO2013121715A1 (ja) *	2012-02-15	2013-08-22	パナソニック株式会社	スピーカ
KR101847947B1 (ko)	2013-03-15	2018-05-28	옵코 아이피 홀딩스 Ⅱ 인코포레이티드	안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en)	2014-08-07	2019-03-05	Opko Ireland Global Holdings, Ltd.	Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
SG10201913863TA (en)	2016-03-28	2020-03-30	Opko Ireland Global Holdings Limited	Methods of vitamin d treatment
WO2018084959A2 (en)	2016-09-30	2018-05-11	Nelson Deanna J	Pharmaceutical quality strontium l-lactate
JP7499259B2 (ja) *	2018-09-25	2024-06-13	ポンスデレオンヘルスデジグネイテッドアクティビティカンパニー	αケトグルタル酸カルシウムを製造するためのプロセス
CN114994195B (zh) *	2022-05-12	2024-12-31	上海应用技术大学	一种枸橼酸铁及其六种有机酸的高效液相色谱分离分析方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5160737A (en) *	1988-05-03	1992-11-03	Perio Products Ltd.	Liquid polymer composition, and method of use
US5602116A (en) *	1988-08-02	1997-02-11	Bone Care International, Inc.	Method for treating and preventing secondary hyperparathyroidism
ATE105170T1 (de) *	1989-01-31	1994-05-15	Yissum Res Dev Co	Dentalzusammensetzung fuer ueberempfindliche zaehne.
FR2651497B1 (fr) *	1989-09-01	1991-10-25	Adir	Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
FR2749759B1 (fr) *	1996-06-17	1999-11-26	Adir	Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
US5792446A (en) *	1997-02-18	1998-08-11	Collagenex Pharmaceuticals, Inc.	Delivery system for administering dentin-hypersensitivity-ameliorating compositions
WO1999034772A1 (en) *	1998-01-09	1999-07-15	Enamelon, Inc.	Solid products and methods for the remineralization and prevention of demineralization of teeth
GB0015745D0 (en) *	2000-06-27	2000-08-16	Shire Holdings Ag	Treatment of bone diseases
NO20014746D0 (no) *	2001-09-28	2001-09-28	Clas M Kjoelberg	Smertelindrende middel
PL1534305T3 (pl) *	2003-05-07	2007-03-30	Osteologix As	Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
CN101010087B (zh) *	2004-05-06	2012-06-27	奥斯泰奥洛吉斯公司	用于制备金属有机盐的高收率和快速的合成方法

2004
- 2004-05-06 EP EP04731307.7A patent/EP1622629B1/en not_active Expired - Lifetime
- 2004-05-06 PL PL04731307T patent/PL1622629T3/pl unknown
- 2004-05-06 AU AU2004237437A patent/AU2004237437B2/en not_active Ceased
- 2004-05-06 WO PCT/DK2004/000326 patent/WO2004098617A2/en active Application Filing
- 2004-05-06 CA CA2524603A patent/CA2524603C/en not_active Expired - Fee Related
- 2004-05-06 JP JP2006504377A patent/JP5049589B2/ja not_active Expired - Fee Related
- 2004-05-06 US US10/556,150 patent/US20060216358A1/en not_active Abandoned
2008
- 2008-12-22 US US12/341,439 patent/US20090191282A1/en not_active Abandoned
2010
- 2010-12-08 AU AU2010249227A patent/AU2010249227B2/en not_active Ceased
2011
- 2011-02-17 JP JP2011032077A patent/JP2011121985A/ja not_active Withdrawn
2012
- 2012-09-20 US US13/623,389 patent/US20130071496A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2524603A1 (en)	2004-11-18
CA2524603C (en)	2013-04-02
EP1622629A2 (en)	2006-02-08
AU2010249227A1 (en)	2011-01-06
JP5049589B2 (ja)	2012-10-17
JP2011121985A (ja)	2011-06-23
US20130071496A1 (en)	2013-03-21
WO2004098617A2 (en)	2004-11-18
EP1622629B1 (en)	2013-07-10
AU2004237437A1 (en)	2004-11-18
WO2004098617A3 (en)	2005-03-31
AU2004237437B2 (en)	2011-01-20
JP2006525241A (ja)	2006-11-09
US20060216358A1 (en)	2006-09-28
US20090191282A1 (en)	2009-07-30
AU2010249227B2 (en)	2011-06-30

Publication	Publication Date	Title
PL1622629T3 (pl)	2013-12-31	Kompozycja do kontrolowanego uwalniania zawierająca sól strontu
GB0209467D0 (en)	2002-06-05	Chemical compounds
GB0322016D0 (en)	2003-10-22	New compounds
GB0205693D0 (en)	2002-04-24	Chemical compounds
GB0203994D0 (en)	2002-04-03	Chemical compounds
EP1592425A4 (en)	2007-01-24	NOVEL ARYLPIPERAZINYL COMPOUNDS
EG23485A (en)	2005-12-05	Chemical compounds
EP1551813A4 (en)	2007-07-11	CHEMICAL COMPOUNDS
GB0203020D0 (en)	2002-03-27	Chemical compounds
HRP20041092A2 (en)	2005-06-30	New pharmaceutical compositions containing filbanserin polymorph a
GB0208224D0 (en)	2002-05-22	Chemical compounds
GB0205176D0 (en)	2002-04-17	Chemical compounds
AU2003290661A8 (en)	2004-06-03	Chemical compounds
AU2003241671A8 (en)	2003-12-31	Controlled-release drug composition
GB0203022D0 (en)	2002-03-27	Chemical compounds
GB0205690D0 (en)	2002-04-24	Chemical compounds
EP1484061A4 (en)	2009-12-23	DRUGS CONTAINING COMPOUNDS OF THE RIBOFLAVIN TYPE
EP1556379A4 (en)	2007-06-13	CHEMICAL COMPOUNDS
GB0205175D0 (en)	2002-04-17	Chemical compounds
GB0205166D0 (en)	2002-04-17	Chemical compounds
SI1622629T1 (sl)	2013-10-30	Sestavek s kontroliranim sproĹˇÄŤanjem, ki vsebuje stroncijevo sol
GB0303086D0 (en)	2003-03-19	New compounds
GB0223354D0 (en)	2002-11-13	Chemical compounds
HUP0302440D0 (en)	2003-09-29	New compounds
IL168113A (en)	2013-04-30	Controlled release vehicles